Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss
Corporate Restructuring and Future Strategy on Monday, March 3, 2008
BOTHELL, Wash., Feb. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will host a conference
call with investors and security analysts on Monday, March 3, 2008, at 11:30
a.m. Eastern time (8:30 a.m. Pacific time) to discuss the Company's corporate
restructuring initiatives and future strategy. To participate in the live
conference call, U.S. residents should dial (800) 901-5259 and international
callers should dial (617) 786-4514. The access code for the live conference
call is 46949609. To access the 24-hour telephone replay, U.S. residents
should dial (888) 286-8010 and international callers should dial
(617) 801-6888. The access code for the replay is 16918791.
Alternatively, to access the live audio webcast for this conference call
or the subsequent archive, please go to Nastech's website at
http://www.nastech.com approximately 15 minutes prior to the conference call
in order to register and download any necessary software.
About Nastech
Nastech is a clinical stage biopharmaceutical company focusing on the
development and commercialization of innovative therapeutic products based on
its proprietary molecular biology-based drug delivery technologies and,
through its wholly-owned subsidiary, MDRNA, Inc., based on its proprietary
ribonucleic acid interference (RNAi) technology. Nastech and its collaboration
partners are developing products for multiple therapeutic areas including
osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory
conditions. Additional information about Nastech is available at
http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this press release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results to
differ materially from those projected or suggested. Factors that could cause
actual results to differ materially from those in forward-looking statements
include, but are not limited to: (i) the ability of Nastech or a subsidiary to
obtain additional funding; (ii) the ability of Nastech or a subsidiary to
attract and/or maintain manufacturing, research, development and
commercialization partners; (iii) the ability of Nastech, a subsidiary and/or
a partner to successfully complete product research and development, including
preclinical and clinical studies and commercialization; (iv) the ability of
Nastech, a subsidiary and/or a partner to obtain required governmental
approvals; and (v) the ability of Nastech, a subsidiary and/or a partner to
develop and commercialize products that can compete favorably with those of
competitors. Additional factors that could cause actual results to differ
materially from those projected or suggested in any forward-looking statements
are contained in Nastech's most recent periodic reports on Form 10-K and Form
10-Q that are filed with the Securities and Exchange Commission. Nastech
assumes no obligation to update and supplement forward-looking statements
because of subsequent events.
Contacts:
Nastech Pharmaceutical Company Inc.
Matthew Haines
Senior Director, Investor Relations and Corporate Communications
(212) 209-3874
ir@nastech.com
SOURCE Nastech Pharmaceutical Company Inc.
Matthew Haines, Senior Director, Investor Relations and Corporate
Communications, Nastech Pharmaceutical Company Inc., +1-212-209-3874,
ir@nastech.com
